This is the authors' abstract. We don't add key points for this paper.
Vismodegib reduces the basal-cell carcinoma tumor burden and blocks growth of new basal-cell carcinomas in patients with the basal-cell nevus syndrome. The adverse events associated with treatment led to discontinuation in over half of treated patients. (Funded by Genentech and others; ClinicalTrials.gov number, NCT00957229.).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: